Icosavax (ICVX) IPO Opens 93% Higher

Today's IPO for Icosavax, Inc. (Nasdaq: ICVX) opened for trading at $29 after pricing 12,133,333 shares of common stock at an initial public offering price of $15.00 per share.

Jefferies, Cowen, Evercore ISI and William Blair are acting as joint book-running managers for the offering.

Icosavax is a biopharmaceutical company leveraging its innovative VLP platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases. Icosavax exclusively licensed the VLP technology for use in several fields, including RSV and hMPV, from the University of Washington. For SARS-CoV-2, Icosavax has a non-exclusive, worldwide (excluding South Korea) license from the University of Washington that will convert to an exclusive license in North America and Europe in 2025. Icosavax is located in Seattle.

You May Also Be Interested In

• YPF Energía Eléctrica S.A. files for proposed NYSE IPO
• SpaceX shares continue lower, hit lowest level since IPO
• Mercator Acquisition Corp. raises $172.5M in Nasdaq IPO